Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation

v3.24.1.u1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2024
Stock-Based Compensation  
Stock-Based Compensation

12.   Stock-Based Compensation

Employee Equity Incentive Plan

On September 20, 2017, the Company established its 2017 Omnibus Equity Incentive Program (the “2017 Plan”) which provides for the granting of equity-based awards to certain employees, directors, independent contractors, consultants and agents. Under the 2017 Plan, the Company may grant non-qualified stock options, stock appreciation rights, restricted stock units, and other stock-based awards.

On April 19, 2021, the Company established its 2021 Omnibus Equity Incentive Plan (“2021 Equity Plan”). The 2021 Equity Plan provides for the grant of stock options (including qualified incentive stock options and nonqualified stock options), stock appreciation rights, restricted stock, restricted stock units, dividend equivalents, and other stock or cash settled incentive awards.

Stock Options

Options become exercisable subject to vesting schedules up to four years from the date of the grant and subject to certain timing restrictions upon an employee’s separation of service and no later than 10 years after the grant date.

A summary of stock option activity as of and for the three months ended March 31, 2024 is as follows:

Stock Option

Weighted Average

Remaining

Number of

Weighted Average

Contractual Life

Aggregate

Options

Exercise Price

(Years)

Intrinsic Value

Outstanding as of December 31, 2023

    

9,992

$

17.01

6.91

$

197,598

Options granted

 

Options exercised

 

(194)

8.78

Options forfeited

 

(23)

28.49

Outstanding as of March 31, 2024

 

9,775

$

17.15

6.67

$

176,726

Options expected to vest as of March 31, 2024

 

2,744

$

25.70

8.07

$

26,257

Options exercisable as of March 31, 2024

 

6,906

$

13.58

6.08

$

149,377

Stock options include grants to executives that contain both market-based and performance-based vesting conditions. There were no stock options granted that contain both market-based and performance-based vesting conditions during the three months ended March 31, 2024. During the three months ended March 31, 2024, there were no stock options exercised and 1,373 market-based and performance-based stock options remain outstanding as of March 31, 2024.

The total intrinsic value of options exercised during the three months ended March 31, 2024 and March 31, 2023 was $5.1 million and $12.8 million, respectively.

The Company’s board of directors (the “Board”) did not declare or pay dividends on any Company stock during the three months ended March 31, 2024 and March 31, 2023.

Restricted Stock Units (“RSUs”)

RSUs are subject to vesting schedules up to four years from the date of the grant and subject to certain restrictions upon employee separation.

A summary of RSUs activity as of and for the three months ended March 31, 2024 is as follows:

    

RSUs

Number of

Weighted Average

Shares

Grant Date Fair Value

Outstanding as of December 31, 2023

4,720

$

28.03

Granted

 

2,387

33.88

Vested

 

(435)

27.13

Forfeited

 

(65)

28.48

Outstanding as of March 31, 2024

 

6,607

$

30.20

The total grant date fair value of RSUs that vested during the three months ended March 31, 2024 was $11.8 million.

Performance Stock Units (“PSUs”)

PSUs are subject to vesting and performance periods of up to approximately three years from the date of the grant.

A summary of PSUs activity as of and for the three months ended March 31, 2024 is as follows:

PSUs

Weighted 

Average Grant 

Number of 

Date Fair 

    

Shares

    

Value

Outstanding as of December 31, 2023

480

$

41.31

Granted

186

41.28

Vested

Forfeited

Outstanding as of March 31, 2024

 

666

$

41.30

The fair market value of PSUs with market-based and service-based vesting conditions granted for the years presented has been estimated on the grant date using the Monte Carlo Simulation model with the following assumptions:

    

2024

Risk‑free interest rate (percentage)

 

3.9 - 4.1

Expected dividend yield (percentage)

 

Expected volatility (percentage)

 

46.7

Stock-based Compensation Expense

Total stock-based compensation expense recorded in the Condensed Consolidated Statements of Operations and Comprehensive Income was as follows:

Three Months Ended

March 31, 

(in thousands)

 

2024

 

2023

Product development

$

7,373

$

4,379

Sales, marketing and customer support

 

5,936

 

3,507

General and administrative

 

6,932

 

3,927

Total stock-based compensation

$

20,241

$

11,813

As of March 31, 2024, unrecognized stock-based compensation expense was $217.7 million, which is expected to be recognized over a weighted-average period of 1.5 years.

Employee Stock Purchase Plan (“ESPP”)

In March 2021, the Board approved the Company’s 2021 ESPP. Purchases are accomplished through participation in discrete offering periods. The ESPP is available to U.S.-based employees and most of the Company’s non-U.S.-based employees. The current offering period began on December 1, 2023 and will end on May 31, 2024. The Company expects the program to continue consecutively for six-month offering periods for the foreseeable future.

Under the ESPP, eligible employees are able to acquire shares of the Company’s common stock by accumulating funds through payroll deductions. The purchase price for shares of common stock purchased under the ESPP is 85% of the lesser of the fair market value of the common stock on (i) the first trading day of the applicable offering period and (ii) the last trading day of the applicable offering period. Employees are required to hold shares purchased for a minimum of six months following the purchase date.

Stock-based compensation expense for the ESPP is recognized on a straight-line basis over the requisite service period of each award. Stock-based compensation expense related to the ESPP totaled $0.3 million and $0.2 million for the three months ended March 31, 2024 and March 31, 2023, respectively.